Analysis of Normal and Malignant Lymphoid Progenitor Cells with Monoclonal Antibodies.
NIOSH 1982 Apr:623-631
The cellular and molecular events which were associated with differentiation of normal and malignant human lymphoid progenitor cells have been studied. A panel of monoclonal antibodies has been produced against the human pre-B acute lymphoblastic leukemia cell line NALM-6-M1. These antibodies were designated BA-1, BA-2, and BA- 3. Monoclonal antibody BA-1 binds primarily to cells in the B- lymphocyte lineage. The antigen recognized by BA-1 is lost as B- cells terminally differentiate into plasma cells. About 80 percent of non-T acute lymphoblastic leukemia (ALL), 90 percent of surface Ig+ nonHodgkins lymphomas, and over 95 percent of surface Ig+ chronic lymphocytic leukemias are reactive with BA-1. BA-1 does not bind to natural killer (NK) cells and is nonreactive with hematopoietic stem cells, making this antibody good for the in-vitro removal of residual leukemic cells prior to autologous bone marrow transplantation. Monoclonal antibody BA-2 binds to a small percentage of lymphoid cells in bone marrow, thymus and peripheral blood. BA-2 binds strongly to about 70 percent of ALL, primarily pre-B type, and weakly to about 20 percent T-cell ALL, and 25 percent of AML. BA-2 also shows strong reactivity with a large number of nonhematopoietic tumors including melanomas and neuroblastomas. By not reacting with stem cells it is also a good candidate for in-vitro removal of residual leukemic cells prior to autologous bone marrow transplantation. BA-3 is serologically identical to J-5, a monoclonal antibody identifying the common ALL antigen.
Chemotherapy; Medical-treatment; Hematopoietic-system; Leukemogenesis; Antibody-response; Lymphatic-system-disorders; Cell-function; Lymphocytes; Blood-analysis;
Proceedings of the Second NCI/EPA/NIOSH Collaborative Workshop: Progress on Joint Environmental and Occupational Cancer Studies, September 9-11, 1981, Rockville, Maryland